image
Lisata Therapeutics, Inc. LSTA
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 2.57
1.18 %
$ 22.1 M
Market Cap
-1.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 22, 2025.

The intrinsic value of one LSTA stock under the worst case scenario is HIDDEN Compared to the current market price of 2.57 USD, Lisata Therapeutics, Inc. is HIDDEN

LSTA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 22, 2025.

The intrinsic value of one LSTA stock under the base case scenario is HIDDEN Compared to the current market price of 2.57 USD, Lisata Therapeutics, Inc. is HIDDEN

LSTA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 22, 2025.

The intrinsic value of one LSTA stock under the best case scenario is HIDDEN Compared to the current market price of 2.57 USD, Lisata Therapeutics, Inc. is HIDDEN

LSTA Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart LSTA

image
1M -2%
6M 3%
1Y -14.0%
3Y -198%
5Y -1260%
All
$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25
FINANCIALS
1 M REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years -25.08%
-22.4 M OPERATING INCOME
12.83%
Growth Rates
1Year 12.83%
3Years 8.29%
5Years -2.21%
7Years 2.93%
10Years 9.03%
-20 M NET INCOME
4.10%
Growth Rates
1Year 4.10%
3Years 10.06%
5Years -0.65%
7Years -3.07%
10Years 9.70%
-19.4 M OPERATING CASH FLOW
3.37%
Growth Rates
1Year 3.37%
3Years 4.53%
5Years -0.50%
7Years 1.07%
10Years 8.47%
13.2 M INVESTING CASH FLOW
30.99%
Growth Rates
1Year 30.99%
3Years 30.86%
5Years -9.19%
7Years -15.00%
10Years 12.45%
-206 K FINANCING CASH FLOW
-53.51%
Growth Rates
1Year -53.51%
3Years -0.08%
5Years -3.26%
7Years 19.39%
10Years -0.07%
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years -25.08%
0 OPERATING INCOME
100.00%
Growth Rates
1Year 12.83%
3Years 8.29%
5Years -2.21%
7Years 2.93%
10Years 9.03%
-4.72 M NET INCOME
-2.47%
Growth Rates
1Year 4.10%
3Years 10.06%
5Years -0.65%
7Years -3.07%
10Years 9.70%
-5.4 M OPERATING CASH FLOW
-19.30%
Growth Rates
1Year 3.37%
3Years 4.53%
5Years -0.50%
7Years 1.07%
10Years 8.47%
9.43 M INVESTING CASH FLOW
578.98%
Growth Rates
1Year 30.99%
3Years 30.86%
5Years -9.19%
7Years -15.00%
10Years 12.45%
-23 K FINANCING CASH FLOW
76.04%
Growth Rates
1Year -53.51%
3Years -0.08%
5Years -3.26%
7Years 19.39%
10Years -0.07%
Balance Sheet Lisata Therapeutics, Inc.
image
Current Assets 34.6 M
Cash & Short-Term Investments 31.2 M
Receivables 900 K
Other Current Assets 2.43 M
Non-Current Assets 424 K
Long-Term Investments 0
PP&E 72 K
Other Non-Current Assets 352 K
89.27 %6.95 %Total Assets$35.0m
Current Liabilities 5.61 M
Accounts Payable 1.28 M
Short-Term Debt 137 K
Other Current Liabilities 4.19 M
Non-Current Liabilities 72 K
Long-Term Debt 0
Other Non-Current Liabilities 72 K
22.59 %73.74 %Total Liabilities$5.7m
EFFICIENCY
Earnings Waterfall Lisata Therapeutics, Inc.
image
Revenue 1 M
Cost Of Revenue 174 K
Gross Profit 826 K
Operating Expenses 23.4 M
Operating Income -22.4 M
Other Expenses -2.42 M
Net Income -20 M
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)1m(174k)826k(23m)(22m)2m(20m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
82.60% GROSS MARGIN
82.60%
Averages
1Year 82.60%
3Years 45.05%
5Years 27.03%
7Years 19.31%
10Years 15.73%
-2240.90% OPERATING MARGIN
-2240.90%
Averages
1Year -2240.90%
3Years -762.79%
5Years -457.67%
7Years -326.91%
10Years -288.34%
-1998.50% NET MARGIN
-1998.50%
Averages
1Year -1998.50%
3Years -681.06%
5Years -408.64%
7Years -291.88%
10Years -249.54%
-67.58% ROE
-67.58%
Averages
1Year -67.58%
3Years -64.10%
5Years -49.43%
7Years -55.22%
10Years -135.08%
-57.10% ROA
-57.10%
Averages
1Year -57.10%
3Years -56.48%
5Years -44.07%
7Years -47.24%
10Years -49.88%
-72.98% ROIC
-72.98%
Averages
1Year -72.98%
3Years -67.77%
5Years -51.59%
7Years -56.92%
10Years -74.14%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Lisata Therapeutics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -20 M
Depreciation & Amortization 174 K
Capital Expenditures 0
Stock-Based Compensation 1.65 M
Change in Working Capital -873 K
Others 697 K
Free Cash Flow -19.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Lisata Therapeutics, Inc.
image
LSTA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Lisata Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary results Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is evaluating Lisata's therapy candidate certepetide in combination with standard-of-care chemotherapy and immunotherapy in pancreatic cancer. It is evaluating the therapy in patients with locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC), rather than metastatic PDAC. proactiveinvestors.com - 2 weeks ago
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide's potential ability to enhance the effectiveness of immunotherapy Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide's potential ability to enhance the effectiveness of immunotherapy globenewswire.com - 2 weeks ago
Lisata Therapeutics expands IP with key patent covering certepetide's chemical structure and uses Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has been issued a new US composition of matter patent for its investigational drug candidate certepetide. The United States Patent and Trademark Office (USPTO) has granted the company US Patent No 12,351,653, which provides protection for certepetide through March 2040, with the possibility of a patent term extension. proactiveinvestors.com - 3 weeks ago
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension globenewswire.com - 3 weeks ago
Lisata Therapeutics and GATC advance AI-driven opioid use disorder therapy - ICYMI Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's deepening collaboration with GATC Health. Mazzo explained that the partnership has evolved due to the complementary strengths of both organisations—Lisata's clinical and regulatory expertise and GATC's AI-powered drug discovery platform, MAT. proactiveinvestors.com - 3 weeks ago
Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer Lisata Therapeutics Inc (NASDAQ:LSTA), in collaboration with the Australasian Gastro-Intestinal Trials Group and the NHMRC Clinical Trials Centre at the University of Sydney, announced positive preliminary results from Cohort B of the ASCEND Phase 2b clinical trial evaluating certepetide in combination with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). The ASCEND trial is a 158-patient, double-blind, randomized, placebo-controlled study assessing the addition of certepetide to standard-of-care gemcitabine and nab-paclitaxel. proactiveinvestors.com - 1 month ago
Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate of drug development using artificial intelligence (AI). The expanded collaboration builds on prior work in which GATC provided AI-based analysis supporting Lisata's certepetide drug candidate. proactiveinvestors.com - 1 month ago
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development Expanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug development globenewswire.com - 1 month ago
Lisata Therapeutics to Present at the 2025 BIO International Convention BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming 2025 BIO International Convention taking place in Boston, MA from June 16 – 19, 2025. globenewswire.com - 1 month ago
Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants John Menditto - VP of IR and Corporate Communications David Mazzo - President and CEO James Nisco - SVP of Finance and Treasury and Chief Accounting Officer Kristen Buck - EVP of R&D and Chief Medical Officer Conference Call Participants Kemp Dolliver - Brookline Capital Market Pete Enderlin - MAZ Partners Operator Welcome to the Lisata Therapeutics First Quarter 2025 Financial Results and Business Update Conference Call. Currently, all participants are in listen-only mode. seekingalpha.com - 2 months ago
Lisata eyes key trial milestones in 2025 as certepetide development gains momentum Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it expects a data-rich year ahead as it advances multiple trials of its lead asset, certepetide, a novel peptide-based therapy being tested in a range of solid tumors. The New Jersey-based company said it remains focused on progressing certepetide through clinical and preclinical studies, with several important data readouts expected over the course of 2025 and into 2026, including results from the second cohort of its ASCEND trial in metastatic pancreatic cancer and preclinical work with Catalent's antibody-drug conjugate (ADC) platform. proactiveinvestors.com - 2 months ago
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 globenewswire.com - 2 months ago
8. Profile Summary

Lisata Therapeutics, Inc. LSTA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 22.1 M
Dividend Yield 0.00%
Description Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Contact 110 Allen Road, Basking Ridge, NJ, 07920 https://www.lisata.com
IPO Date March 1, 1999
Employees 26
Officers Dr. Kristen K. Buck M.D. Executive Vice President of R&D and Chief Medical Officer Mr. John D. Menditto Vice President of Investor Relations & Corporate Communications Mr. James Nisco Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Mr. Gregory S. Berkin Chief Information & Data Protection Officer Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. President, Chief Executive Officer & Director Mr. Tariq Imam Senior Vice President of Business Development & Operations and General Counsel Dr. William K. Sietsema Ph.D. Vice President of Global Regulatory Affairs